ASSESSMENT OF INTRAUTERINE ABORTION OUTCOMES AT 9-12 WEEKS OF GESTATION USING MISOPROSTOL REGIMEN AFTER 24 HOURS OF MIFEPRISTONE AT DONG THAP GENERAL HOSPITAL IN 2022-2023
Main Article Content
Abstract
Background: First trimester abortion can be provide using either medical abortion or surgical techniques. Medical abortion using Mifepristone and Misoprostol can avoid complications associated with surgical priventions. Medical abortion using mifepristone and misoprostol can avoid complication associated with surgical prevention. Medical abortion has been extensively researched worldwide, particularly the use of the Mifepristone-Misoprostol regimen for pregnancies between 9 and 12 weeks gestation. This combined regimen has shown a significantly high success rate ranging from 89% to 97.3%. Shortening the duration of Misoprostol administration after taking Mifepristone offers several advantages, including reducing the waiting time for the expulsion of the pregnancy and alleviating the psychological burden on women undergoing unintended abortions. Objective: To evaluate the outcomes of inpatient medical abortion using the Misoprostol regimen 24 hours after Mifepristone administration, specifically for pregnancies between 9 and 12 weeks gestation. Materials and methods: A case series report was conducted, involving 50 women aged 16 years and above who expressed the desire for inpatient medical abortion at Dong Thap General Hospital from November 2022 to March 2023. Results: The shortened duration of Misoprostol administration after Mifepristone resulted in an effective abortion rate of 88 %. No severe complications were recorded during the study. Less than 10% of the participants experienced minor side effects such as nausea/vomiting, headache, dizziness, and diarrhea. Approximately 95% of the women participating in the study expressed satisfaction with the research method. Conclusion: The Mifepristone-Misoprostol regimen administered 24 hours apart for pregnancies between 9 and 12 weeks gestation demonstrated high efficacy, safety, minimal invasiveness, and high satisfaction levels. Therefore, this method should be considered for routine practice in obstetrics and gynecology hospitals.
Article Details
Keywords
Medical abortion, mifepristone, misoprostol
References
10.1093/ije/dyw270.
2. Oppegaard, Kevin Sunde, et al. What if medical abortion becomes the main or only method of first-trimester abortion? A roundtable of views. 2018. 97(2), 82-85. doi:
10.1016/j.contraception.2017.04.004.
3. Bộ Y Tế. Hướng dẫn quốc gia về các dịch vụ chăm sóc sức khoẻ sinh sản, Quyết định số 4128/QĐ-BYT ngày 29/7/2016 của Bộ trưởng Bộ Y tế. 2016. 403 - 414.
4. Schmidt Hansen, Mia, et al. Initiation of abortion before there is definitive ultrasound evidence of intrauterine pregnancy: A systematic review with meta analyses, J Acta Obstetricia et Gynecologica Scandinavica. 2020. 99(4), 451-458. doi: 10.1111/aogs.13797.
5. Feld, Zoe M, et al. Opioid Analgesia for Medical Abortion: A Randomized Controlled Trial, J Obstetric. , 2020. 135(6), 1485. doi: 10.1097/AOG.0000000000003576.
6. Phạm Quang Nhật, Lê Quang Thanh, Ngô Thị Yên, Hiệu quả và an toàn của phác đồ phá thai nội khoa dùng mifepristone và misoprostol ở thai 9 -12 tuần tại Bệnh viện Từ Dũ. Tạp chí Y học Thành phố Hồ Chí Minh. 2022, 26(1), 59-64.
7. Đặng Thị Ngọc Thơ, Lê Hoài Chương. Đánh giá hiệu quả phá thai nội khoa đến hết 9 tuần bằng việc rút ngắn thời gian sử dụng misoprostol sau mifepristone từ 48 xuống còn 24 giờ. Tạp chí Phụ sản. 2014,12(2),195-198.